Allyx Therapeutics

About:

Allyx Therapeutics is a clinical-stage biotechnology company that develops therapies to reverse neurodegeneration.

Website: https://allyxthera.com

Twitter/X: allyxthera

Top Investors: Bristol-Myers Squibb, Connecticut Innovations, National Institutes of Health, Spring Mountain Capital, Life Science Angels

Description:

Allyx Therapeutics is a clinical-stage biotechnology company that develops therapies to reverse neurodegeneration. Allyx Therapeutics' product is an orally bioavailable small molecule that acts as a silent allosteric modulator, enabling clinicians to get a drug capable of delivering a disease-modifying approach and preserving cognition in patients.

Total Funding Amount:

$13.4M

Headquarters Location:

New Haven, Connecticut, United States

Founded Date:

2018-01-01

Contact Email:

info(AT)allyxthera.com

Founders:

Paul Fonteyne, Stephen Bloch, Stephen M. Strittmatter, Timothy Siegert

Number of Employees:

1-10

Last Funding Date:

2024-10-15

IPO Status:

Private

Industries:

© 2025 bioDAO.ai